Covered recipient · General Payments record
MUSTAFA NAKAWA
Allopathic & Osteopathic Physicians Family Medicine Obesity Medicine
General Payments · PY2019–2024
$1,027.31
- Reported across 53 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $329.54 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $84.65 | 5 |
| ABIOMED | $61.50 | 2 |
| Currax Pharmaceuticals LLC | $51.98 | 3 |
| ABBVIE INC. | $40.38 | 2 |
| Acerta Pharma LLC | $21.41 | 1 |
| PFIZER INC. | $18.97 | 1 |
| Lilly USA, LLC | $18.16 | 1 |
| GlaxoSmithKline, LLC. | $17.91 | 1 |
| Phathom Pharmaceuticals, Inc. | $14.58 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.63 | 02/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105096519 | CMS |
| ABBVIE INC. | $13.75 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105096521 | CMS |
| ABIOMED | $37.36 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142285175 | CMS |
| ABIOMED | $24.14 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142285211 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.41 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104298674 | CMS |
| Currax Pharmaceuticals LLC | $17.67 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513744 | CMS |
| Currax Pharmaceuticals LLC | $16.53 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513742 | CMS |
| Currax Pharmaceuticals LLC | $17.78 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513746 | CMS |
| GlaxoSmithKline, LLC. | $17.91 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116274029 | CMS |
| Lilly USA, LLC | $18.16 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135175147 | CMS |
| Novo Nordisk Inc | $19.79 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097554943 | CMS |
| Novo Nordisk Inc | $17.48 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097069454 | CMS |
| Novo Nordisk Inc | $18.63 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096814831 | CMS |
| Novo Nordisk Inc | $13.37 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097223173 | CMS |
| Novo Nordisk Inc | $15.38 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096946024 | CMS |
| PFIZER INC. | $18.97 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131024119 | CMS |
| Phathom Pharmaceuticals, Inc. | $14.58 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151100339 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.